A5085810268- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
- Medical Imaging Techniques and Applications
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Iron Metabolism and Disorders
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Fungal Infections and Studies
- Retinoids in leukemia and cellular processes
University Hospital Centre Zagreb
2016-2025
University of Zagreb
2016-2025
Klinička bolnica Merkur
2022
Klinički Bolnički Centar Rijeka
2021
Polyclinique Bordeaux Nord Aquitaine
2019
CHU Dijon Bourgogne
2016
Centre Hospitalier Universitaire Henri-Mondor
2016
Western University
2012
CollegeAmerica
2012
The Netherlands Cancer Institute
2010
Abstract Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing 68 HSTLs, we define recurrently mutated driver genes copy-number alterations in disease. Chromatin-modifying genes, including SETD2, INO80, ARID1B, were commonly HSTL, affecting 62% cases. HSTLs manifest frequent mutations STAT5B (31%), STAT3 (9%), PIK3CD for which there currently exist potential targeted therapies. In addition, noted...
High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of needed is unclear. This European intergroup study evaluated impact sequential high-dose (SHDCT) before myeloablative therapy.Patients histologically confirmed, HL were treated two cycles dexamethasone, cytarabine, and cisplatin, those without disease progression randomly assigned. In arm (A), received...
To compare patients with high-risk stage III to IV Hodgkin lymphoma (HL) in the phase European Organisation for Research and Treatment of Cancer 20012 Intergroup trial (Comparison Two Combination Chemotherapy Regimens Treating Patients With Stage or Hodgkin's Lymphoma) who were randomly assigned either doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) etoposide, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP).Patients clinical HL, International Prognostic Score 3...
The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (BV-AVD) in previously untreated, (ClinicalTrials.gov identifier: NCT02292979). BREACH is a multicenter, randomized, open-label, phase II trial. Eligible were age 18-60 years ≥ 1 EORTC/LYSA criterion. Patients randomly assigned (2:1) to four cycles BV-AVD or standard bleomycin, vincristine, (ABVD),...
8002 Background: Escalated BEACOPP and derivatives achieved superior time to treatment failure (FFTF) over COPP/ABVD, resulting in higher overall survival (OS) for advanced HL. However, later clinical trials have failed confirm OS superiority ABVD. Methods: Eligibility criteria: stage III/IV HL, International prognostic score (IPS) ≥ 3, age<60. We compared ABVD (8 cycles) vs. (escalated 4 cycles baseline 4), without irradiation. Randomization was stratified institution IPS. Primary...
Biosimilars are highly similar to the licensed biologic ("reference product"), with no clinically meaningful differences in safety, purity, or potency between two products. This comparative 52-week clinical study evaluated efficacy, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-05280586 (Ruxience™ [a rituximab biosimilar]) versus reference product sourced from EU (MabThera®; rituximab-EU). Subjects CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL) an...
Tumour bulk is an established prognostic factor in Hodgkin lymphoma (HL) but most patients with limited-stage (LS) HL do not have 'bulk' by standard binary definitions. In the RAPID trial, maximum tumor diameter (MTD) was associated risk of relapse for LS-HL achieving PET-negativity after ABVD chemotherapy. We aimed to externally validate these findings H10 trial. Patients stage I/IIA HL, without mediastinal bulk, who achieved were included. 'PET-negative' received 3x plus radiotherapy...
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIa may be major mechanism of activity combination DLBCL.
Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence different antineoplastic treatment modalities outcomes conflicting. Anti-CD20 monoclonal antibodies increase infection. It is unclear whether this affected by choice antibody (rituximab vs. obinutuzumab). To elucidate role therapy COVID-19 outcomes, KroHem collected data patients diagnosed between October 2020 and April 2021. A total 314 were identified, 75...
Acute promyelocytic leukemia (APL) M3 is an acute myeloid (AML) subtype characterized by proliferation of malignant promyelocytes with mature immunophenotype and the translocation t(15;17)(q22;q11), which results in fusion retinoic acid receptor-alpha (RARalpha) gene on chromosome 17 PML 15. There are three morphologic variants: typical hypergranular form microgranular basophilic variants. Although most leukemic cells patients express t(15;17), other cytogenetic abnormalities have also been...